
The US Food and Drug Administration (FDA) has approved Ozempic in a 2.0 mg dose for the treatment of adults with type 2 diabetes.
Ozempic, which is a GLP-1 analog administered once a week, is therefore now approved in the US in 0.5, 1.0 and 2.0 mg doses.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app